Filing Flows › Comparisons › ALLR vs ONCO
Allarity Therapeutics vs Onconetix: ALLR and ONCO compared
Allarity Therapeutics is the larger company: $25K of revenue in its latest quarter (Q1 2026) against $17K for Onconetix (Q2 2026).
Where the money goes: ALLR and ONCO
Allarity Therapeutics (ALLR) · Q1 2026
Allarity Therapeutics, Q1 2026: revenue $25K, net loss $2.8M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Onconetix (ONCO) · Q2 2026
Onconetix, Q2 2026: revenue $17K (-84% year over year), net loss $2.9M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Allarity Therapeutics (ALLR) | Onconetix (ONCO) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $25K | $17K |
| Revenue growth, Y/Y | — | -84% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.8M | −$2.9M |
| Operating cash flow | −$4.5M | −$1.9M |
Questions
Which is bigger, Allarity Therapeutics or Onconetix?
Allarity Therapeutics is the larger company: $25K of revenue in its latest quarter (Q1 2026) against $17K for Onconetix (Q2 2026).
More: Allarity Therapeutics earnings · how Allarity Therapeutics makes money · Onconetix earnings · how Onconetix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 15, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.